This trial is evaluating whether TLR9 Agonist SD-101 will improve 2 primary outcomes and 1 secondary outcome in patients with Lymphoma, Mantle-Cell. Measurement will happen over the course of Up to 60 months.
This trial requires 30 total participants across 1 different treatment group
This trial involves a single treatment. TLR9 Agonist SD-101 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
"It is suggested that both genetic and other causes of lymphoma result in a high rate of genetic errors in b-cells that are associated with a dysfunctional repair mechanism. The accumulation of these errors leads to a B-immunodeficiency condition, which may eventually contribute to lymphoma development." - Anonymous Online Contributor
"The signs and symptoms of lymphoma, b-cell, marginal zone were as follows: persistent vomiting, swollen lymph nodes, enlargement of the spleen, fever, cough, hoarseness, fatigue, loss of appetite. The early signs of lymphoma are the same as those of myeloma." - Anonymous Online Contributor
"The most common forms of lymphoma in the first instance are non-Hodgkin's lymphoma (NHL) and follicular lymphoma. However a wide range of lymphomas can occur in the B-cell, marginal zone of the lymphoid tissue (MLZ). This article aims to offer clinicians with a brief overview the diagnostic features, immunological behaviour, differential diagnosis as well as treatment options for NHL or MLZ." - Anonymous Online Contributor
"When all known treatments such as chemotherapy, radiotherapy, autohemapheresis, immunotherapy and immunoanalogues are used, lymphoma, b-cell, marginal zone still behaves worse than other non-Hodgkin lymphoma groups." - Anonymous Online Contributor
"Approximately 80,000 people in the United States are diagnosed with lymphoma, b-cell, marginal zone a year. The vast majority of these cases are non-Hodgkin's lymphoma and may present with lymphadenopathy, skin lesions, or other extranodal lesions. These cases occur in all age groups, but are more common in older patients." - Anonymous Online Contributor
"There are a variety of treatments commonly available for non-Hodgkin's lymphoma and marginal cell lymphoma. Lymphoblast therapy and peripheral stem cell transplantation are frequently utilized therapeutics for these patients, and are often effective and durable. The prognosis is generally good, although patients at a younger age, those with more serious disease, and women, have an increased survival rate." - Anonymous Online Contributor
"Ibrutinib is an effective new drug in relapsed/refractory marginal zone lymphomas with minimal to no systemic toxicity. A new drug, in combination with a chemotherapeutic regimen, can overcome the poor prognosis associated with marginal B-cell lymphoma and provides a new treatment option in the post-R-CHOP era." - Anonymous Online Contributor
"Ibrutinib, in conjunction with cyclophosphamide and dexamethasone, effectively depletes and induces apoptosis of erythroblasts from erythrokeratosis verruciformis (EV) patients. Because ibrutinib has been associated with drug-induced polycythaemia (PCH), a direct effect on erythroid precursors must be considered plausible." - Anonymous Online Contributor
"The prognosis of MALT lymphoma is excellent. The prognosis of MCL appears to be very poor unless patients are initially diagnosed as early as their first hospital visit with an accompanying diagnosis of CLL and a marrow evaluation is performed within six months. When MCL is evaluated at diagnosis and at presentation while still confined to marrow, it appears to have a survival rate with limited progression to and improved long-term outcomes compared to other BNCLLs evaluated in these two clinical settings." - Anonymous Online Contributor
"Ibrutinib is well tolerated. Commonly encountered adverse events include diarrhea, fatigue, constipation, nausea, peripheral edema, and rash. Patients should be informed of the potential risks with ibrutinib therapy such as skin or GI tract adverse events. Patient counseling on all of these side effects will assist the patient and the healthcare provider in deciding if ibrutinib therapy is effective and how to manage side effects." - Anonymous Online Contributor
"Although data from Phase III randomized clinical trials are encouraging, the use of ibrutinib should be tailored to the individual patient and their disease, as well as to the context within which they will receive treatment." - Anonymous Online Contributor
"Ibrutinib was typically administered in combination with other therapies in the first-line setting to a large cohort of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma/B-cell non-Hodgkin lymphoma. Patients with high baseline levels of the lactate dehydrogenase activity were eligible to participate when appropriate. Clinical trials were registered with the Pharmaceutical Product Development Assistance Program of the Swiss Federal Drug Agency. ClinicalTrials.gov NCT01352276; NCT01357832." - Anonymous Online Contributor